6.
Fischer E, Beuschlein F, Bidlingmaier M, Reincke M
. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord. 2011; 12(1):43-8.
DOI: 10.1007/s11154-011-9163-7.
View
7.
Li X, Liang J, Hu J, Ma L, Yang J, Zhang A
. Screening for primary aldosteronism on and off interfering medications. Endocrine. 2023; 83(1):178-187.
DOI: 10.1007/s12020-023-03520-6.
View
8.
Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Barfacker L
. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014; 64(1):69-78.
DOI: 10.1097/FJC.0000000000000091.
View
9.
Ganesh M, Abadin S, Fogelfeld L
. Adrenal Vein Sampling Without Discontinuation of Mineralocorticoid Receptor Antagonist Therapy. Endocr Pract. 2021; 26(9):953-959.
DOI: 10.4158/EP-2019-0599.
View
10.
Wada T, Inagaki M, Yoshinari T, Terata R, Totsuka N, Gotou M
. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin Exp Nephrol. 2020; 25(2):120-130.
PMC: 7880964.
DOI: 10.1007/s10157-020-01963-z.
View
11.
Okubo J, Frudit P, Cavalcante A, Maciel A, Freitas T, Pilan B
. Contralateral Suppression in Adrenal Venous Sampling Predicts Clinical and Biochemical Outcome in Primary Aldosteronism. J Clin Endocrinol Metab. 2024; 109(9):2282-2293.
DOI: 10.1210/clinem/dgae142.
View
12.
Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U
. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010; 285(39):29932-40.
PMC: 2943305.
DOI: 10.1074/jbc.M110.131342.
View
13.
Yang J, Young M, Cole T, Fuller P
. Mineralocorticoid receptor signalling in primary aldosteronism. J Endocrinol. 2023; 259(1).
DOI: 10.1530/JOE-22-0249.
View
14.
Peng K, Liao H, Chan C, Lin W, Yang S, Tsai Y
. Presence of Subclinical Hypercortisolism in Clinical Aldosterone-Producing Adenomas Predicts Lower Clinical Success. Hypertension. 2020; 76(5):1537-1544.
DOI: 10.1161/HYPERTENSIONAHA.120.15328.
View
15.
Buffolo F, Pieroni J, Ponzetto F, Forestiero V, Rossato D, Fonio P
. Prevalence of Cortisol Cosecretion in Patients With Primary Aldosteronism: Role of Metanephrine in Adrenal Vein Sampling. J Clin Endocrinol Metab. 2023; 108(9):e720-e725.
DOI: 10.1210/clinem/dgad179.
View
16.
Shibata S
. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor and NaCl transport mechanisms in the renal distal nephron. J Endocrinol. 2017; 234(1):T35-T47.
DOI: 10.1530/JOE-16-0669.
View
17.
Naruse M, Murakami M, Katabami T, Kocjan T, Parasiliti-Caprino M, Quinkler M
. International multicenter survey on screening and confirmatory testing in primary aldosteronism. Eur J Endocrinol. 2023; 188(1).
DOI: 10.1093/ejendo/lvac002.
View
18.
Ahmed A, Gordon R, Taylor P, Ward G, Pimenta E, Stowasser M
. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab. 2011; 96(6):1797-804.
DOI: 10.1210/jc.2010-2918.
View
19.
Kayser S, Dekkers T, Groenewoud H, van der Wilt G, Carel Bakx J, van der Wel M
. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab. 2016; 101(7):2826-35.
DOI: 10.1210/jc.2016-1472.
View
20.
Wu S, Yang J, Hu J, Song Y, He W, Yang S
. Confirmatory tests for the diagnosis of primary aldosteronism: A systematic review and meta-analysis. Clin Endocrinol (Oxf). 2019; 90(5):641-648.
DOI: 10.1111/cen.13943.
View